News for Lexaria Bioscience Corp (LXRP)

Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire /

5th study arm in 12-week Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDA

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp. (Na

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / A

Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound®Blood glucose reduction and insulin secretion levels from th

Dr. Gibson joining Lexaria's new scientific advisor board KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (t

Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide KELOWNA, BC / ACCESSWIRE / December 9, 2024

On December 3, 2024, Richard Christopher, the Chief Executive Officer of Lexaria Bioscience Corp, purchased 50,000 shares of the company, according to a SEC Fil

Lexaria Bioscience CEO buys $118,391 in shares

Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and moreGLP-1 drugs expected to generate multi-hundreds of billion

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / November 25, 2024 / Lexaria Bioscience Corp.

DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both

Lexaria commences unique drug distribution study

Atai Life Sciences N.V. (ATAI), a clinical-stage biopharmaceutical company, observed a significant stock movement with a 6.13% rise in share price, reaching $1.

Connaught Biosciences (CNTB) experienced a significant drop in stock price, declining by 5.11%. The current price stands at $1.39 per share with a trading volum

Lexicon Pharmaceuticals (LXRX) experienced a notable stock movement, with shares rising by 5.59%. The stock is currently priced at $1.70 per share, with a tradi

Loading... Loading... Shares of Healthequity Inc HQY rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter fina...

lxrp_8k.htm UNITED STATES SECURITIES AND EXCHANGE...

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.